What this topic covers
Subpart 2B (Educate Patients and Health Care Professionals) of the Content Outline effective June 1, 2022: the duty to consult, written patient information, nonprescription products and devices, and intern pharmacists. These are original practice notes, not documents of the California State Board of Pharmacy or PSI, based on law and FDA labeling in force on January 1, 2027; time limits, thresholds and quantities can change with each year's legislation. Nothing here is medical advice.
Duty to consult
- New drug: oral consultation whenever the prescription drug has not previously been dispensed to the patient (16 CCR section 1707.2(a)(3)).
- Change: a new dosage form, strength or written directions each trigger consultation (16 CCR section 1707.2(a)(4)).
- Patient not present: written notice of the right to consultation and of the pharmacist's hours and telephone number (16 CCR section 1707.2(b)(1)).
- Inpatients: excused except upon the patient's discharge (16 CCR section 1707.2(b)(2)).
- Refusal: no oral consultation when the patient or agent refuses (16 CCR section 1707.2(e)); a technician never consults.
- Private area: required in all pharmacies except hospital inpatient pharmacies (16 CCR section 1714(a)).
Written information and patient rights
- Retail price: a pharmacist or a pharmacist's employee gives it upon request (B&P Code section 4122(b)).
- Impairment label: a written label when the drug may impair driving (B&P Code section 4074(b)).
- Translated directions: upon request, printed on the container, label or a supplemental document (B&P Code section 4076.6(a)).
- Medication Guide: handed directly to each patient or agent when dispensed (21 CFR 208.24(e)).
- Oral contraceptives: a patient package insert to each patient or agent (21 CFR 310.501(a)).
- Teach-back: the patient restates the instructions in her own words, prompted by open-ended questions (theory).
Drug Facts counseling
- Plan B One-Step: if you vomit within 2 hours after taking the medication, call a healthcare professional (Plan B One-Step Drug Facts label, Directions, revised 01/2023).
- Opill: more than 3 hours late, take 1 tablet immediately and use a barrier method during the next 2 days (48 hours); liver problems mean ask a doctor first (Opill Drug Facts label).
- Nicotine patch: 10 or less cigarettes per day, start with STEP 2 (14 mg) for 6 weeks, then STEP 3 (7 mg) for 2 weeks (nicotine patch Drug Facts label, Directions).
- Nicotine gum: use at least 9 pieces per day for the first 6 weeks; do not use more than 24 pieces a day (nicotine gum Drug Facts label, Directions).
- Naloxone: stay until the ambulance arrives; give another dose if the person becomes very sleepy again (NARCAN Drug Facts label, Directions).
- Pseudoephedrine: children ages 6 to 11 years take 1 tablet every 4 to 6 hours, not more than 4 tablets in 24 hours (pseudoephedrine Drug Facts label, Directions).
Devices and education
- Diabetes test device: a glucose meter or test strip sold without a prescription (B&P Code section 4025.2).
- Education: training on drug therapy, disease management and prevention, with no authority to diagnose (B&P Code section 4052(a)(8)).
Intern pharmacists
- Functions: all pharmacist functions under the direct supervision and control of a pharmacist (B&P Code section 4114(a)).
- Ratio: no more than two intern pharmacists at any one time (B&P Code section 4114(b); as of January 1, 2027; check for later changes).
- Self Query Report: dated no earlier than 60 days before the application (16 CCR section 1727.2; as of January 1, 2027; check for later changes).
Sample questions (5)
1. Under 16 CCR section 1707.2, a pharmacist must provide oral consultation whenever the prescription drug:
- is a controlled substance on a federal schedule
- has a lower-cost generic equivalent available
- has not been dispensed to the patient before
- is being paid for under a third-party plan
16 CCR section 1707.2(a)(3) requires oral consultation “whenever the prescription drug has not previously been dispensed to a patient”. The regulation does not tie the duty to a controlled-substance schedule, to the availability of a generic equivalent, or to the payer, so none of those facts triggers consultation under section 1707.2(a).
2. Patient M.D. picks up a refill of the same drug, strength, dosage form and directions that Harbor Point Pharmacy has dispensed to her for years.
She asks no questions, and the pharmacist has no concern about her therapy.
Under 16 CCR section 1707.2, the pharmacist:
- may dispense the refill without oral consultation
- must consult orally, since each dispensing requires it
- must consult orally, but a technician may deliver it
- may dispense, but she must first sign a waiver
16 CCR section 1707.2(a) lists four triggers: a request, the pharmacist's professional judgment, a drug not previously dispensed, or a change in dosage form, strength or written directions. None applies to an unchanged refill. Where consultation is due, the duty rests on the pharmacist and not on a technician, and the regulation requires no signed waiver before an unchanged refill is dispensed.
3. Patient V.S. has taken lisinopril tablets from Cedar Ridge Pharmacy for a year.
Today's new prescription is for the same drug in a higher strength, with the same written directions.
Must the pharmacist provide oral consultation?
- No, because the drug itself was dispensed to her before
- Yes, because a year has passed since her first fill
- No, because the written directions have not changed
- Yes, because the strength differs from the prior fill
Under 16 CCR section 1707.2(a)(4), consultation is required whenever a drug not previously dispensed “in the same dosage form, strength or with the same written directions” is dispensed. A change in any one of the three is enough, so the earlier dispensing of the same drug and the unchanged directions do not excuse the pharmacist. The time elapsed since her first fill is not a trigger named in section 1707.2(a); the new strength is.
4. A pharmacist at Mission Oaks Pharmacy fills a prescription for patient L.P. for a drug previously dispensed to her as tablets.
The new prescription is for the same drug and strength as an oral liquid, with the same directions.
The pharmacist:
- may skip consultation, since the drug and strength match
- must consult orally, since the dosage form is new to her
- must consult orally when the prescriber requests it
- may give her a printed leaflet instead of consulting
16 CCR section 1707.2(a)(4) requires oral consultation when a prescription drug is dispensed in a dosage form not previously dispensed to the patient, even if the drug and strength are the same. Prescriber approval is not a condition of the duty. Written information is the required substitute only when the patient is not present, as section 1707.2(b) describes, and not when she is at the counter.
5. Under 16 CCR section 1707.2(d), when the pharmacist deems it warranted in professional judgment, oral consultation shall also include:
- the pharmacy's acquisition cost for the dispensed drug
- the pharmacist's own continuing education record
- the action to be taken in the event of a missed dose
- the National Drug Code of the dispensed product
16 CCR section 1707.2(d)(7) lists “action to be taken in the event of a missed dose” among the additional topics for consultation when the pharmacist deems it warranted. The same subdivision names the name and description of the drug, route, dosage form, refill information and contraindications. Acquisition cost, the pharmacist's education record, and the National Drug Code do not appear in section 1707.2(d).